Increasing cell density beyond a threshold decreases both cell survival and VEGF secretion. by Rachel Coy (4027016)

Search duration decreases with target value and increases with the environment’s probability of containing a reward target. by Michael R. Traner (11836571)

Decreased reductase activity and increased round body formation in the <i>gpsA</i> mutant. by Dan Drecktrah (36180)

Risk assessment for hospital admission in patients with COPD; a multi-centre UK prospective observational study by Jilles M. Fermont (3746068)

“…In total, 291 of 714 individuals experienced 762 hospitalised AECOPD during five-year follow up. Poorer performance of SPPB was associated with both higher rate (IRR 1.08 per 1 point decrease, 95% CI 1.01 to 1.14) and increased length of stay (IRR 1.18 per 1 point decrease, 95% CI 1.10 to 1.27) for hospitalised AECOPD. …”

Decreases in locomotor responses to a single METH injection in <i>Ptprz</i>-KO mice. by Akihiro Fujikawa (122649)

RNF5 loss decreases ERK and Akt activation, CDK1 and Smo expression and KSHV lytic replication in PEL cells. by Xiaojuan Li (351842)

MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. by Rodrigo Ibarra-García-Padilla (19697623)

Decreased respiratory performance of children and adolescents with myelomeningocele who use a wheelchair – preliminary data by E.J. Martins (7141313)

Full-length PRR expression increases and sPRR secretion decreases in the absence of PACE4 in mouse. by Amro H. Mohammad (15081540)

TBEV-induced translational arrest results in the decreased protein levels of GAPDH, HPRT1, and viperin. by Martin Selinger (3195987)

Cycloheximide (CHX) treatment decreases production of rRNA transcripts by POLR1 and POLR3. by Martin Selinger (3195987)

“…<p>(A) DAOY cells were treated with CHX (100 μg/ml) for either 6 or 14 hours; for metabolic RNA labelling, 5-EU was added 2 hours before the sample collection. …”

Effects of SNPs on the Protein Stability, Increasing or Decreasing. by Mirza Jawad Ul Hasnain (8351388)

Loss of nsp14-ExoN activity decreases recombination frequency and alters recombination junction patterns across the genome. by Jennifer Gribble (10005444)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects: